Mike Hershkovitz
Healthcare & Rehab Technology Expert
May 7, 2025
In today’s hospital ecosystem, clinical performance and financial sustainability are deeply intertwined. Two crucial metrics—Diagnosis Related Group (DRG) and Geometric Mean Length of Stay (GMLOS)—form the backbone of modern hospital reimbursement. As hospitals seek to optimize length of stay while ensuring high-quality care, technologies like LiteRun are emerging as essential allies.
Quick Recap: What are DRG and GMLOS?
- DRG (Diagnosis Related Group) is a classification system that groups hospital patients by diagnosis, procedure, and resource usage. It determines a flat-rate reimbursement regardless of actual cost or length of stay.
- GMLOS (Geometric Mean Length of Stay) reflects the average number of days patients with a specific DRG stay in the hospital, calculated using a geometric mean to reduce the impact of extreme outliers.
Hospitals are expected to treat patients efficiently and effectively within the GMLOS window—any deviation affects resource utilization, reimbursement margins, and sometimes, hospital ratings.
Where LiteRun Comes In
LiteRun, a lightweight, air-based lower-body mobility device, was designed to accelerate patient recovery and mobility, particularly in acute and post-acute care settings. Its ability to offload body weight safely and comfortably enables early mobilization for patients recovering from neurological events, orthopedic surgeries, or critical illness.
Here’s why that’s important:
Early Mobility = Shorter Length of Stay
Studies have consistently shown that delays in mobility directly correlate with prolonged hospitalization. LiteRun supports safe, early ambulation, reducing the risk of complications like muscle deconditioning, pneumonia, and falls—all of which can push patients beyond the DRG’s GMLOS threshold.
Alignment with DRG Reimbursement Strategy
When a patient’s stay extends beyond the GMLOS benchmark, hospitals do not receive additional payment unless outlier thresholds are met. By enabling earlier movement and improving functional independence, LiteRun helps hospitals stay within the reimbursed window—without compromising outcomes.
Enhancing Patient Throughput in High-Volume DRGs
DRGs such as:
- DRG 470 (Major Joint Replacement),
- DRG 291 (Heart Failure and Shock with MCC), and
- DRG 064 (Intracranial Hemorrhage or Stroke with MCC) are all mobility-sensitive. LiteRun supports early mobilization in these populations, potentially reducing LOS and increasing turnover capacity.
Real-World Application
Imagine a stroke patient under DRG 064. The GMLOS is roughly 4.7 days. If immobility delays their therapy start or increases risk for complications, they may remain hospitalized for 7+ days—resulting in resource strain and unreimbursed costs. LiteRun can be deployed within 24–48 hours post-stroke, helping initiate movement earlier, reducing fall risk, and restoring gait function faster.
Beyond Metrics: A Human-Centered Win
Hospitals may track DRGs and GMLOS for financial reasons, but the real benefit of LiteRun lies in the patient experience:
- Walking sooner
- Gaining independence
- Reducing psychological stress and delirium
- Feeling more confident about recovery
These clinical advantages contribute to better outcomes, higher HCAHPS scores, and stronger hospital reputation—adding indirect value beyond the immediate reimbursement landscape.
Conclusion
As value-based care and cost-efficiency dominate healthcare priorities, LiteRun’s technology stands at the intersection of innovation and necessity. By helping hospitals stay within GMLOS limits, reducing complications, and improving patient mobility earlier, LiteRun directly supports both clinical and financial success in the DRG-based system.
For hospitals, it’s not just about getting patients discharged faster—it’s about getting them home stronger.
For additional information and a demo meeting: mike.hershkovitz@literun.com